We have previously reported a reduced incidence of preeclampsia in women who were at risk and were taking vitamin C (1000 mg/d) and vitamin E (400 IU/d) supplements. In this study, we determined whether supplementation in the same cohort was associated with an improvement in indices of placental dysfunction and oxidative stress toward values determined in women who were at low risk of preeclampsia. STUDY DESIGN: Seventy-nine women who were at high risk and who were taking vitamin supplements and 81 who were taking placebos were compared with 32 women who were at low risk and who were not taking supplements who were studied simultaneously. RESULTS: Indices of oxidative stress and placental function were abnormal in the placebo group. When the placebo group was compared with the women who were at low risk, ascorbic acid, plasminogen activator inhibitor-2, and placenta growth factor concentrations were decreased; and 8-epi-prostaglandin F 2tt , leptin, and the plasminogen activator inhibitor-1/-2 ratio were increased. In the group that received vitamin supplements, ascorbic acid, 8-epi-prostaglandin F2a, leptin, and plasminogen activator inhibitor-1/-2 values were similar to women who were at low risk. CONCLUSION: Antioxidant supplementation in women who were at risk of preeclampsia was associated with improvement in biochemical indices of the disease. (Am J Obste! Gynecol 2002;187:777-84.) 
the already dysfunctional placenta and lead to maternal endothelial cell activation, a hallmark of the disease.P Antioxidant supplementation may therefore offer potential for prevention or amelioration of preeclampsia. We recently undertook the first prospective randomized, placebo-controlled trial of antioxidants in high-risk women to assessthe potential benefit of prophylactic supplementation in the prevention of preeclampsia.f Vitamin C and E supplementation was associated with a reduced incidence of preeclampsia and a decrease in an index of the disease in maternal plasma, the plasminogen activator inhibitor {PAI)-1/PAI-2ratio, a measure of endothelial and placental dysfunction.? We have characterized recently the gestational profile in the maternal blood of this and other indices of oxidative stress and placental dysfunction in the placebo group, according to adverse outcome.f In this analysis of both placebo-and vitamin-treated women, we have addressed the hypothesis that antioxidant supplementation would improve placental function, reduce oxidative stress, and reverse the abnormalities that are observed towards values in a group of low-riskwomen who were recruited simultaneously.
Ascorbic acid and a-tocopherol measurements were used to assess oxidative stress and the efficacy of supplementation. Measurement of the isoprostane, 8-epi- In view of the role of dyslipidemia in the generation of lipid peroxides, the profile of several lipid species was determined. Placental function was assessed by the measurement ofPAI-2, leptin, and placenta growth factor (PIGF).
PAI-l provided an assessment of endothelial function. than those for 8-epi-PGF 2Cl were measured on at least four occasions in most of the women (75%-84%, depending on the marker; mean, 77%).
Methods

Subjects
Biochemical assays
Indices of antioxidant status and oxidative stress. Samples for ascorbic acid analysis were stored in 2% metaphosphoric acid. Ascorbic acid and uric acid were determined by reverse-phase high-pressure liquid chromatography (lower limit of detection, 5 nmol/L; intra-assay coefficient of variation [CV], 2.2%; interassay CV, 3.5%).11 a-Tocopherol was assayed by reverse-phase high-pressure liquid chromatography with detection at 292 nm (lower limit of detection, 10 nmol/L; intra-assay CV,2.1%; interassay CV, 3.9%) 12and corrected for plasma cholesterol. Samples for analysis of plasma 8-epi-PGF 2Cl were collected into burylated hydroxytoluene (20 umol/L), indomethacin (15 umol.T.). and trisodium citrate (blood/citrate ratio, 9:1). After centrifugation, supernatants were mixed with burylated hydroxytoluene (20 umol/L). Total (sum of free and esterified) plasma 8-epi-PGF2Cl was assessed in a subgroup of women by gas chromatography mass spectrometry,13as previously described. Because of a loss of ,some samples during the preparative stages of the assay, data were available for 8-epi-PGF 2a in 45 women taking placebo, 50 women taking supplements, and 24 low-risk women. Analysis of the characteristics of the patients from whom samples were available indicated that they were representative of the groups as a whole.
Indices of placental function PAl-2 was determined by enzyme-linked immunosorbent assay (EUSA; Tintelize, Biopool International, Sweden; lower limits of detection, 6 ng/mL; intra-assay CV,3.7%; interassay CV,3.0%). Serum leptin was evaluated by radioimmunoassay with 125-labeled human leptin (UNCO Research, Inc, St Charles, Mo; lower limit of detection, 0.5 ng/mL; intra-assayCV,4.5%; internssay CV,4.9%). PlGFwas evaluated by EUSA (R&Dsystems, Abingdon, UK; lower limit of detection, 7 pg/mL; intraassay CV,5.6%-7.0%; interassay cv, 10.9%-11.8%).
Index of endothelial function. PAl-l was determined by EUSA (Tintelize, Biopool International; lower limit of detection, 0.5 ng/mL; intra-assay CV,3.3%; interassay CV, 2.9%).
Others. Plasma triglycerides were measured with an enzymatic colorimetric test (UNIMATE 5 TRIG, Roche/ BCl, Lewes, Sussex, UK) as was total cholesterol (UNIMATE 5 CHOL, Roche/BCI). High-density lipoprotein (HDL)cholesterol was determined by detergent-based isolation and enzyme-linked colorimetric detection (DIRECT HDL CHOLESTEROL, Randox Laboratories Co, Antrim, Northern Ireland). Low-densitylipoprotein (LDL) cholesterol was estimated by calculation from triglycerides and HDL cholesterol. Apo A-I and Apo B were evaluated by immunoturbidimetry (Dade/Behring, Milton Keynes, UK).
Statistical analysis. Graphs were drawn that showed the means and SE for weeks 20 to 36. For seven measures
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(8-epi-PGF2Cl, leptin, PAl-I, PAl-2, PAl-I/PAl-2 ratio, triglycerides, and vitamin Ez'cholesterol ratio), log transformations and geometric means were used. The mean values were calculated for each patient for values obtained after the onset of treatment/placebo (weeks 24-36). The main comparisons between treatment groups were based on these summary scores.I? with the use of multiple regression. For the randomized groups, corrections were made for the pretreatment values at weeks 16 or 20.15 For selected variables that showed consistent changes over time, a second summary score was calculated for each subject: the weekly rate of change was based on linear regression.J? Standard statistical models were used for sensitivity analyses; terms for ethnicity and parity were added to the regression models that were described.
Percentage differences from the reference group are given with 95% CI, with robust standard errors. Significance at the 5% level is claimed when the CI excluded 0% (no effect). Data were analyzed in Stata, version 6.0 (StataCorp, College Station, Tex).
Results
c
The study entry details of the subjects are given in Table I . Although women were recruited sequentially for both low-and high-risk groups, there were differences in parity and ethnic composition, with more multiparous women and more African and Caribbean women in the high-risk group. There were also fewer smokers in the low-risk compared with the high-risk group. Pregnancy outcome details are shown in Table II . As previously reported, significantly fewer women had preeclampsia if they were taking the vitamin supplements (6/79 women) than if they were taking the placebo preparations (21/81 women), with no other significant differences in clinical outcome between the two trial groups.f Fewer than 10% of women in any group were taking low-dose multivitamin preparations, which contained <100 mg of vitamin C and <40 IV of vitamin E. Seven percent of the women in the placebo group and 6% of the women in the vitamin supplement group were taking aspirin; no low-riskwomen took aspirin.
Biochemical analyses Indices of antioxidant status and oxidative stress. Plasma ascorbic acid concentrations were 32% lower (95% CI, 46%-18%) in the high-risk women taking placebo compared with the low-risk group. Ascorbic acid was 45% higher (95% CI, 30%~0%) in the group taking supplements compared with the group taking placebo (as previously reportedv), which achieved concentrations similar to those of the low-riskwomen (6% difference from low risk; 95% CI, -9% to +22%; Fig 1, A) . Plasma a-tocopherol concentrations (corrected for plasma cholesterol) were similar in placebo and low-riskgroups (difference, -4%; 95% CI, -9% to +2%). In the vitamin supplement group, plasma atocopherol was 31% higher (95% CI, 24%-38%) than in the placebo group as reported previouslyf and 34% higher (95% CI, 24%-44%) than in the low-riskwomen (Fig 1, B) .
There were no significant changes in plasma 8-epi-PGF 2 <l concentrations with gestation in the low-riskgroup. Baseline prerandomization plasma concentrations were elevated in the women who took placebo and vitamin supplements at 20 weeks of gestation compared with the low-riskgroup (difference, 40%; 95% CI, 5%-88%). Concentrations were raised in the placebo group (difference, 53%; 95% CI, 10%-114%) for the remainder of gestation, whereas vitamin supplementation was associated with a progressive full to values not significantly different from low-riskcontrol subjects at 36 weeks of gestation (Fig 1, 0, No relationship wasapparent between ascorbic acid and 8-epi-PGF 2 <l. At 32 weeks of gestation, the 63% difference in a-tocopherol between vitamin and placebo groups was associated with a significant decrease (difference, -16%; 95% CI, -28% to -1 %) in plasma 8-epi-PGF 2 <l. Similarly, the 53% increase in a-tocopherol at 36 weeks of gestation was associated with a reduction in this index of lipid peroxidation (difference, -13%; 95% CI, -23% to -2%).
Uric acid increased over weeks 20 to 36 of gestation in all women. Uric acid concentrations were 12% higher (95% CI, 2%-23%) in women who took placebo than in low-riskwomen and 10% (95% CI, -1 % to -20%) higher in the vitamin-treated group. There was no significant effect of vitamin supplementation (Fig 1, D) .
Indices of placental insufficiency.Plasma concentrations of PAl-2 increased with gestation in all groups but were consistently lower in the placebo group than in the lowrisk group (difference, -31 %; 95% CI, -41 % to -12%). The vitamin-supplement group had values that were intermediate between the low-riskand placebo groups (difference from low-riskgroup, -19%; 95% CI, -31 % to -4%; difference from placebo group, 9%; 95% CI, -2% to +21%), but the difference in vitamin-supplement and placebo groups did not achieve significance (Fig 2, A) .
Serum leptin concentration showed a marked increase in the placebo group and was 28% (95% CI, 6%-55%) higher than in low-riskwomen. In the vitamin-supplement group, the rise in leptin concentration was less marked, being only 19% (95% Cl, -1 % to +44%) greater than and not significantly different from the low-riskwomen (Fig 2,  B) . Correcting for maternal body mass index at booking had no significant effect on these differences. PIGF concentrations rose and then fell towards the end of gestation in low-riskwomen. High-risk women showed a very different profile; PIGFwaslower than control subjects in both the placebo (difference, -42%; 95% CI, -55% to -27%) and the vitamin-supplement group (difference, -53%; 95% CI, -64% to -39%). There wasthus little or no effect of supplementation (the vitamin-supplement group was 10% lower than the placebo group; 95% CI, -26% to +8%; Fig 2, 
O.
Index of endothelial function and PAI-IIPAI-2 ratio. The PAl-l profile was similar in all groups (Fig 3, A) . In low-risk women the PAl-l/PAl-2 ratio decreased over gestation, but the fall was blunted in the placebo group, with the ratio being 40% greater (95% CI, 10%-78%) over the study period. In the vitamin group, as previously reported.f there was a significant decrease (difference, -23%; 95% CI, -36% to -7%) in the slope of the PAl-l/PAI-2 ratio in the vitamin-supplement versus the placebo groups (Fig 3, B) , but values remained 17% higher (95% CI, -8%-48%) than low-risk women.
Others. There were no significant differences between groups in any of the lipid parameters that were evaluated. (Table Ill) , Adjusting for ethnicity had only marginal influence on the results for all biochemical parameters that were investigated and did not affect significance or conclusions.
Comment
Supplementation with vitamins C and E in women at increased risk of preeclampsia was associated with improvement of some relevant indices of oxidative stress and placental dysfunction towards values that were observed in a group of healthy women. Most previous investigations of biochemical markers of preeclampsia have been of a cross-sectional nature; this study therefore presents novel data that describe gestational profiles in a group of women at-risk of the development of pre- 20 2.
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Plasma ascorbic acid in the low-riskpregnant women, as reported by others.If was lower than published values for nonpregnant subjects, most likely a reflection of raised plasma volume but possiblyindicative of a mild state of oxidative stress.' Although a decrease in plasma ascorbic acid concentration is recognized in women with established preeclampsia, I we are not aware of any previous reports that described abnormally low concentrations in high-risk subjects earlier before the onset of clinical disease. An increase in metabolic consumption, as described in the plasma of women with established preeclampsia,' is the most likely the explanation, the probable cause being an underlying increase in free radical generation from the placenta and from activated maternal endothelium and leucocytes.l However, variable dietary vitamin intake between groups cannot be discounted and must be formally assessed in future studies. Differences in self-administered supplements between placebo and low-riskgroups might also playa role, but <10% of the women in each group were taking supplements, which is an unlikely confounding factor. Smoking is associated with depletion of plasma ascorbic acid, but only 5% of the women in the placebo group were smokers.
Additional evidence for oxidative stress wassuggested by the early and sustained elevation of plasma concentrations of the marker of lipid peroxidation (8-epi-PGF2o)in the high-risk group, an observation made previously in women with established preeclampsia+ Because little is known of the renal production or metabolism of isoprostanes nor of the implications of renal dysfunction in preeclampsia, urinary concentrations were not considered as a reliable index of oxidative stress for this study, despite a recent report to the contrary.l? Plasma 8-epi-PGF 2a concentrations in the vitamin-supplement group fell to values similar to c.ao Longitudinal evaluation of PAl-l and PAl-l/PAl-2 ratio in plasma from control subjects who were at low risk (.) and from women who were at increased risk of preeclampsia in placebo (e) and vitamin supplementation (.) groups. A, PAl-I. B, PAl-l/PAl-2 ratio. Data are given as mean ± SEM. Axes do not include O.
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those of low-riskwomen and were inversely related to the a-tocopherol concentration, which strongly indicates that vitamin supplementation prevented lipid peroxidation. Because 8-epi-PGF 2a is enzymatically cleaved from isoprostanes that are synthesized in the plasma mernbrane.? the data reflect protective action by a-tocopherol at the level of the lipid bilayer. In turn, this may lower the risk of maternal vascular dysfunction and the onset of preeclampsia. The rationale for the use ofa combination of vitamins C and E in this study lay,in part, in the synergy between the two vitamins that is demonstrated in vitro and in vivo.IS Vitamin E is considered pivotal in breaking the cycle of lipid peroxidation; vitamin C acts to regenerate oxidized vitamin E to the reduced form, thus enhancing the potential of vitamin E to prevent lipid peroxidation. Reports of plasma concentrations of vitamin E in established preeclampsia are variablel: because a-tocopherol is lipophilic and membrane-associated, plasma concentrations may not provide a faithful indicator of the redox state. In this study, plasma a-tocopherol was similar in the low-riskwomen and the high-risk placebo group and increased to values substantially above those of the low-risk women on supplementation.
The sustained elevation in uric acid in the high-risk group could also reflect oxidative stress, as a by-product of stimulation of the xanthine/xanthine oxidase pathwaylOthat arises from placental ischemia/reperfusion, but the contribution of placental uric acid to the maternal plasma concentration is debated. Reduced renal clearance may also be a factor. The lack of effect of vitamin supplementation in the high-risk group may reflect this diversity of origin.
Established preeclampsia is associated with dyslipidemia; plasma triglycerides and cholesterol are substantially increased. However, no abnormalities of the lipid profile in the high-risk placebo were apparent. This reflects the divergence of lipid profiles in the 2 principal abnormal outcome groups (preeclampsia and small-forgestational-age infantsj.f Fetal growth restriction without preeclampsia is associated with lower maternal plasma concentrations of cholesterol.l? and analysis by outcome has shown that one outcome group effectivelycancels out the other.f Plasma leptin concentrations increase in normal pregnancy. 20 ,21The placenta appears to be the source, although there may be a contribution from maternal adipocytes. Leptin is further increased in preeclampsia, and placental hypoxia has been implicated.22 A recent longitudinal study showed a gestational increase in serum leptin in women who later experienced preeclampsia,23which was confirmed here. Furthermore, leptin concentrations in the vitamin-supplement group were lowered and not significantly different to those of the low-riskgroup, possibly reflecting improved placental perfusion as a result of decreased free radical damage and/or lipid peroxidation. Antioxidant-induced inhibition of leucocyte or placental cytokine production could also provide an explanation because some cytokines stimulate leptin synthesis. , A raised PAI-1/PAI-2 ratio has been demonstrated in women with established preeclampsia." and we have now shown that the ratio is increased from 16 to 22 weeks of gestation onwards in high-risk women compared to lowrisk control subjects. This was attributable to blunting of the gestational rise in PAI-2, as reponed previously.7, 24 The reduction in PAI-2may be due to reduced placental mass, because PAI-2is synthesized by trophoblast. As we reponed previouslyf the PAI-1/PAI-2 ratio was significantly reduced in the vitamin-supplement group compared with the placebo group and was predominantly due to an increase in PAI-2,because PAI-1was similar in all three groups. PA1-1 is principally of placental endothelial vascular origin and is raised in the maternal circulation in established preeclampsia.V+ Indeed, analysis of the placebo group data by outcome shows an increase in PAI-1in high-risk placebo group women who later had preeclampsia.f However, the rise was very modest, and other endothelial markers that have been shown more recently to increase in the maternal blood (eg, vascular endothelial growth factor) may be more appropriate for future appraisal of endothelial function.
Maternal concentrations of PIGFare reported to be abnormally low in women with established preeclampsia, and a lowvalue may predate the onset of the disease. 25 In the present study, PIGF concentrations were reduced throughout gestation in both high-risk groups compared with the low-riskwomen. The lack of any beneficial effect of vitamin supplementation, in contrast to the improvement in the other placental markers studied, suggests that a reduction in PIGFmay be integral to the cause of the disease, rather than a consequence of placental insufficiency.
Inevitably, the number of samples that were available for analysis decreased toward term as women were delivered, some prematurely and because of methodologic difficulties; fewer samples than anticipated were analyzed for~pi-PGF 2n.Nonetheless, longitudinal studies of this size in preeclampsia are scarce, and important differences were observed between the study groups in this, the first investigation of prophylactic antioxidant supplementation in high-risk women.
All the low-riskwomen who volunteered for the study during the course of the clinical trial formed the control group. This had the advantage that the samples from all groups were similarly treated and stored for the same pe-riod, but there were significant differences in ethnicity, parity, and number of smokers between high-and lowrisk groups; numbers were fewer in the low-risk group. There was, however, no evidence from the sensitivity analyses that were performed to suggest that these factors contributed to any of the differences that were observed between low-and high-risk groups.
In conclusion, this study has shown a disturbance of plasma indices of placental dysfunction and oxidative stress among women who are at risk of preeclampsia, approximately one quarter of whom eventually had the disease. Improvement in these markers and the associated significant reduction in occurrence of preeclampsia in the group who took vitamin C and E supplements lends strong support to the hypothesis that oxidative stress plays a pivotal role in the cause of the disease.
